<div id="readability-page-1"><div><p><span>Mokari Atabak Chief Financial Officer of Corcept Therapeutics Inc [CORT] filed a Form 4 on December 3, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:</span></p><div><table><tbody><tr><td><span>Date</span></td><td><span>12/2/25</span></td></tr><tr><td><span>Transaction</span></td><td><span>Surrender(1)</span></td></tr><tr><td><span>Shares</span></td><td><span>118</span></td></tr><tr><td><span>Price</span></td><td><span>$79.78</span></td></tr><tr><td><span>Value</span></td><td><span>$9,414</span></td></tr></tbody></table></div><p><span>Ending Holdings: 14,559 - Direct</span></p><ul><li><span>(1)</span></li><li><span>Surrender of shares back to company to pay option exercise cost and/or resulting tax liability.</span></li></ul><p><span>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.</span></p><p><span>Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.</span></p><span> </span></div></div>

CORT

<p>Corcept Therapeutics Inc's CFO, Mokari Atabak, surrendered 118 shares back to the company on December 2, 2025, to cover option exercise costs and tax liabilities. The shares were valued at $9,414, with a price of $79.78 per share. Mokari's direct holdings now total 14,559 shares.</p>

CFO Mokari Surrenders 118 Of Corcept Therapeutics Inc [CORT]